07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Tubulin Binding agent: Interim Phase I data

In a Phase I trial in 27 patients with advanced cancer, dose limiting toxicity for oral ENMD-1198 was established at 550 mg/m 2/day with 2 cases of grade 4 neutropenia. Four patients have experienced stable...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Company News

PR Pharma cardiovascular news

PR Pharmaceuticals filed for Chapter 11 bankruptcy in November. The company's pipeline includes PulmoLAR , a long-acting injectable formulation of 2-methoxyestradiol (a non-estrogenic metabolite of estradiol) in Phase I testing to treat pulmonary arterial hypertension...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Company News

EntreMed cancer, autoimmune news

EntreMed restructured and reduced headcount by 30 (59%) to 21 to lower costs. The company will focus on its ENMD-2076 , a dual-acting aurora A and tyrosine kinase inhibitor in Phase I testing to treat...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Company News

PR Pharma, SurModics deal

SurModics acquired the drug delivery assets of PR Pharmaceuticals for $3 million up front and up to $6 million in milestones. SurModics also will take over PR Pharma's drug delivery partnerships and will co-develop PR...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

EntreMed preclinical data

In rats, 30 and 100 mg/kg of oral 2ME2 significantly delayed the onset and reduced the severity of collagen-induced arthritis compared with controls. In rats with arthritis, 50 mg/kg twice daily and 100 and 300...
07:00 , May 12, 2008 |  BC Week In Review  |  Clinical News

Panzem NCD 2-methoxyestradiol: Development discontinued

EntreMed reported in its earnings that in March it discontinued development of Panzem NCD for oncology indications because further development would “require the commitment of a disproportionate amount of resources.” The product was in Phase...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Clinical News

Panzem NCD 2-methoxyestradiol: Interim Phase II data

Interim data from an open-label Phase II trial in 29 evaluable patients showed that Panzem NCD plus Avastin bevacizumab produced 27 cases of stable disease. Median follow-up time was >8 months. Median progression-free survival and...
08:00 , Feb 4, 2008 |  BioCentury  |  Finance

Ebb & Flow

Carl Icahn has parlayed a 4.2% stake in...
01:02 , Jan 29, 2008 |  BC Extra  |  Clinical News

EntreMed reports Panzem data

EntreMed (NASDAQ:ENMD) said interim data in 29 evaluable patients who received Panzem NCD 2-methoxyestradiol plus Avastin bevacizumab showed that 27 patients (87%) had stable disease and two (7%) had progressive disease as their best response....
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

EntreMed preclinical data

In a mouse model of NSCLC, animals treated with 200 mg/kg of oral ENMD-1198 lived longer compared with animals receiving 6 mg/kg of cisplatin (p=0.0001). ENMD-1198 is a second-generation 2-methoxyestradiol ( 2ME2 ) analog. Data...